SaaStr: “When growth starts slowing, there are five critical questions every founder needs to answer honestly. Not the sanitized versions you might present to your board, but the brutal, unvarnished truth…#1. Are We Less Competitive Than We Were? #2. Has the Market Changed? #3. Are the New Execs and Leaders We’ve Hired Working Out? #4. Are We Moving Fast Enough Anymore? #5. Do We Need to Do a Partial Reset?”
Russ Roberts: “Each individual on the team has specific job descriptions, often. And they inevitably tend to think, if they’re not careful, that that’s their job. It’s not their job. Their job is to achieve the greater goal, whatever it is that the organization is pushing toward. And I think leadership is really about reminding people of that in a way that makes their heart sing, rather than is a boring mantra that they get sick of hearing. And, that’s hard. It’s not easy to do. Because everybody forgets it.”
Mint: “India’s macro fundamentals are strong, yet foreign investors are pulling back from Indian equities. As stocks stay relatively overvalued, AI disrupts IT jobs, private capital investment remains sluggish and the export outlook dims, our growth story must find fresh ideas or risk losing its lustre.”
WSJ: “Researchers aren’t merely slowing aging; they’re learning how to reverse it. Artificial intelligence is supercharging that ambition. Thanks to AI, the process of identifying and developing new drugs, once a decadelong slog, is being compressed into months. AI can design molecules to target precise regions of a protein, simulate how they’ll behave in the body, use massive computing power to ensure they don’t bind to anything else in the body, and predict immune reactions to the drugs—all before a single human clinical trial begins. This convergence of computation and biology will usher in an era not only of curing disease but of preventing it altogether. AI is allowing scientists to reach biological pathways that medicine couldn’t even touch before.”
